Role of amino acids at positions 34, 296, and 486 of cytochrome P450 2D6 in the stimulatory and inhibitory effects of psychotropic agents on dopamine formation from p-tyramine

References

• Bertilsson L, Alm C, De Las Carreras C, Widen J, Edman G, Schalling D. 1989. Debrisoquine hydroxylation polymorphism and personality. Lancet. 1(8637):555.
   PubMed Web of Science ®Google Scholar
• Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. 1992. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 34(3):262–265.
   PubMed Web of Science ®Google Scholar
• Funae Y, Kishimoto W, Cho T, Niwa T, Hiroi T. 2003. CYP2D in the brain. Drug Metab Pharmacokinet. 18(6):337–349.
   PubMedGoogle Scholar
• Hackett JC. 2018. Membrane-embedded substrate recognition by cytochrome P450 3A4. J Biol Chem. 293(11):4037–4046.
   PubMed Web of Science ®Google Scholar
• Haduch A, Bromek E, Daniel WA. 2013. Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters. Pharmacol Rep. 65(6):1519–1528.
   PubMed Web of Science ®Google Scholar
• Hiroi T, Imaoka S, Funae Y. 1998. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun. 249(3):838–843.
   PubMed Web of Science ®Google Scholar
• Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y, Funae Y. 1996. Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol. 51(8):1041–1050.
   PubMed Web of Science ®Google Scholar
• Keks NA, Hope J, Keogh S, Copolov DL. 2018. Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant. Australas Psychiatry. 26(5):537–540.
   PubMed Web of Science ®Google Scholar
• Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K. 2000. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol. 50(1):31–34.
   PubMed Web of Science ®Google Scholar
• Liu ZQ, Cheng ZN, Huang SL, Chen XP, Ou-Yang DS, Jiang CH, Zhou HH. 2001. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. Br J Clin Pharmacol. 52(1):96–99.
   PubMed Web of Science ®Google Scholar
• Llerena A, Edman G, Cobaleda J, Benítez J, Schalling D, Bertilsson L. 1993. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand. 87(1):23–28.
   PubMed Web of Science ®Google Scholar
• Marez D, Legrand M, Sabbagh N, Lo Guidice JM, Spire C, Lafitte JJ, Meyer UA, Broly F. 1997. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 7(3):193–202.
   PubMedGoogle Scholar
• Matar HE, Almerie MQ, Sampson SJ. 2018. Fluphenazine (oral) versus placebo for schizophrenia. Cochrane Database Syst Rev. 6(6):CD006352.
   PubMed Web of Science ®Google Scholar
• McFadyen M, Melvin WT, Murray GI. 1998. Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. Biochem Pharmacol. 55(6):825–830.
   PubMed Web of Science ®Google Scholar
• Nishida Y, Fukuda T, Yamamoto I, Azuma J. 2000. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics. 10(6):567–570.
   PubMedGoogle Scholar
• Niwa T, Hiroi T, Tsuzuki D, Yamamoto S, Narimatsu S, Fukuda T, Azuma J, Funae Y. 2004. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 129(1-2):117–123.
   PubMedGoogle Scholar
• Niwa T, Murayama N, Imagawa Y, Yamazaki H. 2015. Regioselective hydroxylation of steroid hormones by human cytochromes P450. Drug Metab Rev. 47(2):89–110.
   PubMed Web of Science ®Google Scholar
• Niwa T, Murayama N, Yamazaki H. 2008. Heterotropic cooperativity in oxidation mediated by cytochrome P450. Curr Drug Metab. 9(5):453–462.
   PubMed Web of Science ®Google Scholar
• Niwa T, Murayama N, Yamazaki H. 2011. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition. Curr Drug Metab. 12(5):412–435.
   PubMed Web of Science ®Google Scholar
• Niwa T, Narita K, Okamoto A, Murayama N, Yamazaki H. 2019. Comparison of steroid hormone hydroxylations by and docking to human cytochromes P450 3A4 and 3A5. J Pharm Pharm Sci. 22(1):332–339.
   PubMed Web of Science ®Google Scholar
• Niwa T, Okada K, Hiroi T, Imaoka S, Narimatsu S, Funae Y. 2008b. Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain. Biol Pharm Bull. 31(3):348–351.
   PubMed Web of Science ®Google Scholar
• Niwa T, Shizuku M, Yamano K. 2017. Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P450 2D6. Arch Biochem Biophys. 620:23–27.
   PubMed Web of Science ®Google Scholar
• Niwa T, Sugimoto S. 2019. Inhibitory and stimulatory effects of selective serotonin reuptake inhibitors on cytochrome P450 2D6-mediated dopamine formation from p-tyramine. J Pharm Pharm Sci. 22(1):585–592.
   PubMed Web of Science ®Google Scholar
• Niwa T, Yanai M, Matsumoto M, Shizuku M. 2018. Effect of cytochrome P450 (CYP) 2D6 genetic polymorphism on the inhibitory action of antidepressants on CYP2D6-mediated dopamine formation from p-tyramine. J Pharm Pharm Sci. 21(1):135–142.
   PubMed Web of Science ®Google Scholar
• Niwa T, Yasumura M, Murayama N, Yamazaki H. 2014. Comparison of catalytic properties of cytochromes P450 3A4 and 3A5 by molecular docking simulation. Drug Metab Lett. 8(1):43–50.
   PubMedGoogle Scholar
• Philips SR, Rozdilsky B, Boulton AA. 1978. Evidence for the presence of m-tyramine, p-tyramine, tryptamine, and phenylethylamine in the rat brain and several areas of the human brain. Biol Psychiatry. 13(1):51–57.
   PubMed Web of Science ®Google Scholar
• Rendic S. 2002. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 34(1-2):83–448.
   PubMed Web of Science ®Google Scholar
• Saito T, Gutiérrez Rico EM, Kikuchi A, Kaneko A, Kumondai M, Akai F, Saigusa D, Oda A, Hirasawa N, Hiratsuka M. 2018. Functional characterization of 50 CYP2D6 allelic variants by assessing primaquine 5-hydroxylation. Drug Metab Pharmacokinet. 33(6):250–257.
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 270(1):414–423.
   PubMed Web of Science ®Google Scholar
• The Pharmacogene Variation (PharmVar) Consortium. The Human Cytochrome P450 (CYP) Allele Nomenclature Database 2018. Launched on March 20, PharmVar. Available at: https://www.pharmvar.org/gene/CYP2D6. Updated July 10, 2021. [accessed Jul 28 2021].
   Google Scholar
• Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. 1981. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn. 4(11):879–885.
   PubMedGoogle Scholar
• Yu A, Kneller BM, Rettie AE, Haining RL. 2002. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J Pharmacol Exp Ther. 303(3):1291–1300.
   PubMed Web of Science ®Google Scholar
• Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. 2004. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 32(11):1201–1208.
   PubMed Web of Science ®Google Scholar